Combination therapy of infliximab and thiopurines, but not monotherapy with infliximab or vedolizumab, is associated with attenuated IgA and neutralisation responses to SARS-CoV-2 in inflammatory bowel disease
Wellens J., Edmans M., Obolski U., McGregor C.G.C., Simmonds P., Turner M., Jarvis L., Skelly D., Dunachie S., Barnes E., Eyre D.W., Colombel J.F., Wong S.Y., Klenerman P., Lindsay J.O., Satsangi J., Thompson C.P. Combination therapy of infliximab and thiopurines, but not monotherapy with infliximab or vedolizumab, is associated with attenuated IgA and neutralisation responses to SARS-CoV-2 in inflammatory bowel disease. Gut Vol.71 No.9 (2022) , 1919-1922. 1922. doi:10.1136/gutjnl-2021-326312 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/85602
Title
Combination therapy of infliximab and thiopurines, but not monotherapy with infliximab or vedolizumab, is associated with attenuated IgA and neutralisation responses to SARS-CoV-2 in inflammatory bowel disease
